ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years
Kathleen M. McAndrews
Matched on ORCID iD 0000-0002-4092-4991; OpenAlex author ID A5037799954; NIH RePORTER profile ID 11105100. Sources: OpenAlex.
Their work
- Papers
- 12 (first author 1, last author 0)
- Trials
- 0
- Grants
- 1
- Labs led
- 1
- Collaborators
- 35
2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers, 1 grant
Papers 12
- Oncogenic KRAS Regulates Secretion of Extracellular Vesicles and Surface Membrane Charge via Regulation of Phosphatidylserine in Pancreatic Cancer. Co-author DOI 10.1021/acsnano.6c08263↗
- CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. Co-author DOI 10.1038/s44318-026-00854-5↗
- Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Co-author DOI 10.1038/s41467-025-63718-2↗
- An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer. Co-author DOI 10.1126/scitranslmed.adt5511↗
- Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Co-author DOI 10.1126/science.adh4567↗
- KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. First author DOI 10.1016/j.ccell.2023.07.002↗
- Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Co-author DOI 10.1016/j.devcel.2023.07.025↗
- Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Co-author DOI 10.1016/j.ccell.2022.06.011↗
- Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-20-1484↗
- Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2021.108990↗
- Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras G12D in pancreatic cancer. Co-author DOI 10.26508/lsa.202000875↗
- Generation and testing of clinical-grade exosomes for pancreatic cancer. Co-author DOI 10.1172/jci.insight.99263↗
Grants 1
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Raghu Kalluri · 12 shared papers, 2018–2026 · strength 1.87
- Paper Oncogenic KRAS Regulates Secretion of Extracellular Vesicles and Surface Membrane Charge via Regulation of Phosphatidyl… DOI 10.1021/acsnano.6c08263↗
- Paper CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. DOI 10.1038/s44318-026-00854-5↗
- Paper Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. DOI 10.1126/science.adh4567↗
- Krishnan K. Mahadevan · 7 shared papers, 2022–2026 · strength 1.15
- Paper CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. DOI 10.1038/s44318-026-00854-5↗
- Paper Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. DOI 10.1126/science.adh4567↗
- Paper Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. DOI 10.1038/s41467-025-63718-2↗
- Anirban Maitra · 6 shared papers, 2018–2026 · strength 0.88
- Paper CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. DOI 10.1038/s44318-026-00854-5↗
- Paper Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. DOI 10.1038/s41467-025-63718-2↗
- Paper An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreat… DOI 10.1126/scitranslmed.adt5511↗
- Sujuan Yang · 6 shared papers, 2018–2025 · strength 0.77
- Paper Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. DOI 10.1038/s41467-025-63718-2↗
- Paper Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to pr… DOI 10.1016/j.ccell.2022.06.011↗
- Paper KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated ki… DOI 10.1016/j.ccell.2023.07.002↗
- Yang Chen · 4 shared papers, 2022–2024 · strength 0.61
- Paper Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. DOI 10.1126/science.adh4567↗
- Paper Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis … DOI 10.1016/j.devcel.2023.07.025↗
- Paper Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to pr… DOI 10.1016/j.ccell.2022.06.011↗
- Timothy Paul Heffernan · 3 shared papers, 2023–2026 · strength 0.48
- Paper CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. DOI 10.1038/s44318-026-00854-5↗
- Paper An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreat… DOI 10.1126/scitranslmed.adt5511↗
- Paper KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated ki… DOI 10.1016/j.ccell.2023.07.002↗
- Paola A. Guerrero · 3 shared papers, 2023–2026 · strength 0.48
- Paper CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. DOI 10.1038/s44318-026-00854-5↗
- Paper An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreat… DOI 10.1126/scitranslmed.adt5511↗
- Paper KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated ki… DOI 10.1016/j.ccell.2023.07.002↗
- Huamin Wang · 2 shared papers, 2022–2024 · strength 0.33
- Haoqiang Ying · 2 shared papers, 2023 · strength 0.28
- Paper Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis … DOI 10.1016/j.devcel.2023.07.025↗
- Paper KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated ki… DOI 10.1016/j.ccell.2023.07.002↗
- Julienne L. Carstens · 2 shared papers, 2021–2022 · strength 0.26
- Paper Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis i… DOI 10.1016/j.celrep.2021.108990↗
- Paper Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resis… DOI 10.1158/2159-8290.cd-20-1484↗
- Elizabeth J. Shpall · 2 shared papers, 2018–2025 · strength 0.25
- Mayela Carolina Mendt · 2 shared papers, 2018–2025 · strength 0.25
- Paul A. Spezza · 1 shared paper, 2026 · strength 0.24
- Florian Gebauer · 1 shared paper, 2026 · strength 0.24
- Christoph Kahlert · 1 shared paper, 2026 · strength 0.24
- Aislyn P. Schalck · 1 shared paper, 2026 · strength 0.20
- Navid Sobhani · 1 shared paper, 2026 · strength 0.20
- Vincent Bernard · 1 shared paper, 2026 · strength 0.20
- Rachna T. Shroff · 1 shared paper, 2025 · strength 0.18
- Valerie S. Kalluri · 1 shared paper, 2025 · strength 0.18
- Gauri Rajani Varadhachary · 1 shared paper, 2025 · strength 0.18
- Brandon George Smaglo · 1 shared paper, 2025 · strength 0.18
- Shubham Pant · 1 shared paper, 2025 · strength 0.18
- Benson Chellakkan Selvanesan · 1 shared paper, 2025 · strength 0.15
- Fredrik I. Thege · 1 shared paper, 2025 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.